Latest Zoledronic acid Stories
Results from a German study demonstrated no improvement in disease-free survival among patients with breast cancer who were treated with dose-dense chemotherapy and the bisphosphonate ibandronate.
The addition of zoledronic acid to adjuvant endocrine therapy increased bone mineral density and reduced the risk for disease recurrence among postmenopausal women with early hormone receptor-positive breast cancer.
Researchers have proven the continuing effectiveness of treating patients with estrogen receptor-positive premenopausal breast cancer with adjuvant zoledronic acid in addition to adjuvant endocrine treatment including ovarian function suppression.
An osteoporosis drug protects against the bone damaging effects of certain breast cancer medications. According to this study, some breast cancer patients could take zoledronic acid in addition to their anti-cancer medications to maintain bone health.
A new study has found that an osteoporosis drug protects against the bone damaging side effects of certain breast cancer medications.
A new study suggests adding zoledronic acid to a drug regimen for patients with early stage breast cancer does not improve outcome.
A drug used to protect bone may extend survival in older breast cancer patients.
A trial investigating the use of zoledronic acid to aid chemotherapy for breast cancer has found a significant benefit for post-menopausal women, according to results presented at the 2011 European Multidisciplinary Cancer Congress today (Sunday).
- Emitting flashes of light; glittering.